



Northview LifeSciences Congratulates Abcellera Biologics Inc. on Their Successful US\$483Million Nasdaq IPO

“We have been involved with Abcellera both personally and through Northview since Dr. Carl Hansen and his team started the business,” said Doug Janzen, Managing Director of Northview LifeSciences. “I was an early investor and a previous member of the Board of Directors and we are so proud and slightly amazed at what the team at Abcellera has accomplished. Their journey is only beginning, and we expect many more successes in the coming years. In less than 12 months they developed one of the first Monoclonal Antibody therapies for the treatment of COVID-19 and we are confident Abcellera will be a globally important Biotech company and will continue to change the world.”

Awesome job guys!

Doug Janzen
Managing Director Northview LifeSciences